Portal de Periódicos da CAPES

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

2020; Cell Press; Volume: 182; Issue: 6 Linguagem: Inglês

10.1016/j.cell.2020.08.002

1097-4172

Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, Anne‐Gaëlle Goubet, Agathe Dubuisson, Lisa Derosa, Carole Almire, Clémence Hénon, Olivier Kosmider, Nathalie Droin, Philippe Rameau, Cyril Catelain, Alexia Alfaro, Charles Dussiau, Chloé Friedrich, Élise Sourdeau, Nathalie Marin, Tali‐Anne Szwebel, Delphine Cantin, Luc Mouthon, Didier Borderie, Marc Deloger, Delphine Bredel, Séverine Mouraud, Damien Drubay, Muriel Andrieu, Anne-Sophie L’Honneur, Véronique Saada, Annabelle Stoclin, Christophe Willekens, Fanny Pommeret, Frank Griscelli, Lai Guan Ng, Zheng Zhang, Pierre Bost, Ido Amit, Fabrice Barlési, Aurélien Marabelle, Frédéric Pène, Bertrand Gachot, Fabrice André, Laurence Zitvogel, Florent Ginhoux, Michaëla Fontenay, Éric Solary,

Immune responses and vaccinations

Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14LowCD16High monocytes, accumulation of HLA-DRLow classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10LowCD101−CXCR4+/− neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation.